Q1 EPS Forecast for Avalo Therapeutics Boosted by Analyst

Avalo Therapeutics, Inc. (NASDAQ:AVTX) – Analysts at HC Wainwright increased their Q1 2026 earnings per share estimates for Avalo Therapeutics in a note issued to investors on Wednesday, March 25th. HC Wainwright analyst M. Kapoor now anticipates that the company will post earnings of ($1.10) per share for the quarter, up from their previous estimate of ($1.76). HC Wainwright currently has a “Buy” rating and a $40.00 price target on the stock. The consensus estimate for Avalo Therapeutics’ current full-year earnings is ($19.07) per share. HC Wainwright also issued estimates for Avalo Therapeutics’ Q2 2026 earnings at ($1.04) EPS, Q3 2026 earnings at ($0.94) EPS, Q4 2026 earnings at ($0.97) EPS, FY2026 earnings at ($4.02) EPS and FY2027 earnings at ($4.90) EPS.

A number of other brokerages also recently issued reports on AVTX. Guggenheim initiated coverage on Avalo Therapeutics in a report on Monday, February 2nd. They set a “buy” rating and a $50.00 price target on the stock. BTIG Research reissued a “buy” rating and issued a $40.00 target price on shares of Avalo Therapeutics in a research report on Tuesday, March 24th. Weiss Ratings restated a “sell (d-)” rating on shares of Avalo Therapeutics in a research note on Friday, January 9th. Finally, Mizuho raised shares of Avalo Therapeutics to a “strong-buy” rating in a report on Thursday, December 18th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Avalo Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $42.25.

Avalo Therapeutics Stock Performance

Shares of NASDAQ AVTX opened at $13.89 on Friday. The stock has a market capitalization of $316.55 million, a P/E ratio of -2.42 and a beta of 0.84. The stock’s fifty day moving average is $15.47 and its 200 day moving average is $15.81. Avalo Therapeutics has a 52 week low of $3.39 and a 52 week high of $20.72.

Avalo Therapeutics (NASDAQ:AVTX) last posted its quarterly earnings data on Monday, March 23rd. The company reported ($0.37) EPS for the quarter, topping analysts’ consensus estimates of ($1.54) by $1.17. The company had revenue of $0.06 million for the quarter, compared to the consensus estimate of ($0.21) million.

Institutional Trading of Avalo Therapeutics

A number of hedge funds have recently bought and sold shares of AVTX. Velan Capital Investment Management LP lifted its stake in shares of Avalo Therapeutics by 38.4% in the 2nd quarter. Velan Capital Investment Management LP now owns 154,972 shares of the company’s stock worth $773,000 after purchasing an additional 43,000 shares during the period. Patient Square Capital LP bought a new stake in Avalo Therapeutics during the third quarter valued at approximately $1,271,000. Cantor Fitzgerald L. P. purchased a new stake in Avalo Therapeutics during the third quarter valued at approximately $1,083,000. Boothbay Fund Management LLC increased its holdings in Avalo Therapeutics by 1,916.6% during the third quarter. Boothbay Fund Management LLC now owns 228,297 shares of the company’s stock valued at $2,902,000 after buying an additional 216,976 shares during the last quarter. Finally, Ally Bridge Group NY LLC bought a new position in Avalo Therapeutics in the third quarter worth approximately $2,264,000. Hedge funds and other institutional investors own 87.06% of the company’s stock.

Insider Buying and Selling at Avalo Therapeutics

In other news, insider Mittie Doyle sold 25,492 shares of the stock in a transaction on Monday, March 16th. The stock was sold at an average price of $16.15, for a total transaction of $411,695.80. Following the transaction, the insider directly owned 3,622 shares of the company’s stock, valued at $58,495.30. This represents a 87.56% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 3.03% of the stock is owned by insiders.

About Avalo Therapeutics

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.